MARCHF8

Across TCGA pan-cancer cohorts, MARCHF8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MARCHF8 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MARCHF8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MARCHF8 expression acts as an unfavorable survival marker.

ESCA, LIHC, and LUAD are the cancer types where MARCHF8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.108	0.703	<.001	36	view →
LIHC	OS	Median	All	0.033	0.784	<.001	24	view →
LUAD	OS	Median	All	0.258	0.787	.018	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MARCHF8–ESCA (OS)

Open the ESCA breakdown →